Literature DB >> 9042670

International Continence Society "Benign Prostatic Hyperplasia" Study: background, aims, and methodology.

P Abrams1, J L Donovan, J J de la Rosette, W Schäfer.   

Abstract

The International Continence Society Benign Prostatic Hyperplasia Study (ICS-BPH) was devised in response to the perceived underutilization of urodynamics in the diagnosis of benign prostatic obstruction (BPO), together with the apparent reliance on symptoms alone when selecting patients for invasive therapies, despite evidence that lower urinary tract symptoms (LUTS) had poor diagnostic specificity for BPO. The ICS-BPH Study is an international multicenter study employing a wide-ranging patient-completed questionnaire, with questions on symptoms, bothersomeness, quality of life, and sexual function. In addition, each patient underwent multiple urine flow studies and standardized urodynamic investigations (phase I). Phase II was an observational assessment of outcome following a range of treatments: conservative, medical, and surgical. Phase III included data from randomized controlled trials involving a wide range of therapies. One thousand, two hundred and seventy-one patients (mean age, 66 years) were included in phase I from 12 countries: 18% of patients were unobstructed, 22% mildly obstructed, and 60% obstructed on pressure flow studies; 83% of patients performed at least two flow studies. The ICS-BPH Study will allow definitive statements to be made concerning the diagnostic potential of a wide range of LUTS, and will define the place of urine flow studies, describe patients who will need pressure flow studies prior to invasive treatment, and identify those likely to experience an adverse outcome. Although an aim of the study is to produce a diagnostic symptom score, there is considerable doubt as to whether this can be achieved where aging and a variety of lower urinary tract dysfunctions often coexist.

Entities:  

Mesh:

Year:  1997        PMID: 9042670

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  6 in total

1.  Transcriptional repression of Caveolin-1 (CAV1) gene expression by GATA-6 in bladder smooth muscle hypertrophy in mice and human beings.

Authors:  Ettickan Boopathi; Cristiano Mendes Gomes; Robert Goldfarb; Mary John; Vittala Gopal Srinivasan; Jaber Alanzi; S Bruce Malkowicz; Hasmeena Kathuria; Stephen A Zderic; Alan J Wein; Samuel Chacko
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Factors influencing efficacy endpoints in clinical trials for new oral medicinal treatments for overactive bladder: a systematic literature review and meta-analysis.

Authors:  Shingo Iino; Masayuki Kaneko; Mamoru Narukawa
Journal:  Int Urol Nephrol       Date:  2018-04-12       Impact factor: 2.370

3.  Symptom Based Clustering of Men in the LURN Observational Cohort Study.

Authors:  Gang Liu; Victor P Andreev; Margaret E Helmuth; Claire C Yang; H Henry Lai; Abigail R Smith; Jonathan B Wiseman; Robert M Merion; Bradley A Erickson; David Cella; James W Griffith; John L Gore; John O L DeLancey; Ziya Kirkali
Journal:  J Urol       Date:  2019-05-23       Impact factor: 7.450

Review 4.  Economics of lower urinary tract symptoms (LUTS) in older people.

Authors:  U Azam; M Castleden; D Turner
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  GATA-6 and NF-κB activate CPI-17 gene transcription and regulate Ca2+ sensitization of smooth muscle contraction.

Authors:  Ettickan Boopathi; Joseph A Hypolite; Stephen A Zderic; Cristiano Mendes Gomes; Bruce Malkowicz; Hsiou-Chi Liou; Alan J Wein; Samuel Chacko
Journal:  Mol Cell Biol       Date:  2012-12-28       Impact factor: 4.272

6.  Development of a quality of life scale specific for patients with benign prostatic hyperplasia.

Authors:  Kamil Cam; Talha Muezzinoglu; Omer Aydemir; Recep Buyukalpelli; Gokhan Toktas; Hakan Gemalmaz
Journal:  Int Urol Nephrol       Date:  2013-02-19       Impact factor: 2.370

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.